Enrollment continues in RECONNECT, a confirmatory pivotal Phase 3 trial of Zygel in patients with Fragile X syndrome; topline results expected first-half 2024 $44.4 million in cash and cash. | May 16, 2023
Enrollment continues in RECONNECT, a confirmatory pivotal Phase 3 trial of Zygel in patients with Fragile X syndrome; topline results expected first-half 2024 European Commission granted orphan. | March 29, 2023
Enrollment continues in RECONNECT, a confirmatory pivotal Phase 3 trial of Zygel™ in patients with Fragile X syndrome; topline results expected first-half 2024 European Commission granted. | March 28, 2023
14.11.2022 - Enrollment continues in RECONNECT, a confirmatory pivotal Phase 3 trial of Zygel in patients with Fragile X syndrome (FXS); topline results expected second-half 2023 $55.9 million in cash and cash equivalents at September 30, 2022; Cash runway into .